Related Experiment Video
Updated: Jun 5, 2026
06:19
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
Topical agents for idiopathic distal colitis and proctitis
1Centre for Inflammatory Bowel Diseases, Department of Gastroenterology, Fremantle Hospital, Fremantle, Western Australia, Australia. ian.lawrance@uwa.edu.au
Journal of Gastroenterology and Hepatology
|December 24, 2010
Summary
Topical agents like 5-aminosalicylic acid (5-ASA) are effective for distal colitis (DC) and proctitis. Novel topical therapies show promise for resistant disease, but require more rigorous study.
Area of Science:
- Gastroenterology
- Inflammatory Bowel Disease
- Colorectal Medicine
Background:
- Rectal topical agents are effective for distal colitis (DC) and proctitis with infrequent side effects.
- Topical 5-aminosalicylic acid (5-ASA) is superior to oral 5-ASA and topical steroids for distal colon conditions.
- Resistant DC poses management challenges, necessitating novel therapeutic approaches.
Purpose of the Study:
- To review the efficacy of established topical therapies for DC and proctitis.
- To explore data on novel topical agents for managing resistant DC.
- To highlight the need for randomized controlled trials on new topical treatments.
Main Methods:
- Literature review of established and novel topical therapies for DC and proctitis.
- Analysis of clinical, endoscopic, and histological outcomes.
- Assessment of safety profiles, including side effects and adrenal suppression risk.
Main Results:
- Established topical 5-ASA agents show better outcomes than oral formulations and topical steroids.
- Novel topical agents like butyrate, cyclosporine, and tacrolimus are being investigated for resistant DC.
- Most novel agents lack robust evidence due to small, open-label studies.
Conclusions:
- Topical 5-ASA is a preferred treatment for proctitis and DC due to efficacy and safety.
- New topical agents offer potential for refractory DC but require validation through randomized controlled trials.
- Further research is critical to establish the clinical utility of novel topical therapies for distal colitis.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...